RecruitingNot a traditional drug phaseobservationalRules rewrite

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-…

Q: Is NCT07039110 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

Q: What phase is NCT07039110?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Q: Can PlainTrials tell me if I qualify for NCT07039110?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.

Official registry: https://clinicaltrials.gov/study/NCT07039110 · AbbVie · enrollment listed as 700

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 700 people at 84 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

The Real-World Impact of Risankizumab on the Quality of Life and Cumulative Life Course Impairment (CLCI) in Patients With Moderate-to-Severe Plaque Psoriasis (DREAM)

Primary outcome (registry wording): Proportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1

Who it is for (from inclusion criteria)

Ages 18 Years to any
Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment
Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines
Decision to treat with risankizumab is made prior to and independently of study participation

Who the registry excludes

History of a sleep disorder diagnosis which the patient is currently being treated for
Current or recent (within the last 30 days) participation in an treatment clinical trial or an watch-and-measure (no experimental treatment required) study
Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason

Public study contact (from the registry)

Julieta Gonzalez Blanco

844-663-3742

julieta.gonzalezblanco@abbvie.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

84 listed

Dermatology Research Institute - Blackfoot Trail /ID# 276722 — Calgary, Alberta, Canada (recruiting)
Rejuvenation Dermatology - Edmonton Downtown /ID# 276688 — Edmonton, Alberta, Canada (recruiting)
Winnipeg Clinic /ID# 276751 — Winnipeg, Manitoba, Canada (recruiting)
Wiseman Dermatology Research /ID# 276847 — Winnipeg, Manitoba, Canada (recruiting)
Cca Medical Research /ID# 276944 — Ajax, Ontario, Canada (recruiting)
Quinte dermatology /ID# 277497 — Belleville, Ontario, Canada (recruiting)
Dermatrials Research /ID# 276714 — Hamilton, Ontario, Canada (completed)
Lovegrove Dermatology /ID# 276797 — London, Ontario, Canada (recruiting)
Lynderm Research Inc /ID# 276755 — Markham, Ontario, Canada (recruiting)
Rejuvenation Dermatology Clinic Oakville /ID# 277492 — Oakville, Ontario, Canada (recruiting)
JRB Research inc. /ID# 277730 — Ottawa, Ontario, Canada (recruiting)
Factor Dermatology /ID# 278610 — Ottawa, Ontario, Canada (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseHamburg

PsoBest - The German Psoriasis Registry

Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.

NCT01848028 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf

RecruitingNot a traditional drug phaseBerlin, State of Berlin

Not a traditional drug phase: testing Glucocorticoid treatment for Osteoporosis

Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.

NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit

RecruitingPhase 3Ciudad Autonoma de Buenos Aires, Buenos Aires

Phase 3: testing Deucravacitinib for Plaque Psoriasis

The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.

NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

FAQ about this NCT record

Is NCT07039110 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07039110?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07039110?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary